News

Riociguat demonstrated significantly improved exercise capacity in a Phase II study in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) as compared to baseline

The study showed that after 24 weeks, children treated with Xolair suffered 31% fewer clinically significant exacerbations than those receiving placebo or dummy drug (p=0.007). The study therefore

The study showed sustained improvements in lung function for up to four years (p

However, there was clear evidence of clinical activity with improvements in the secondary endpoints of progression-free survival and response rate when Avastin was added to Tarceva compared to

The two companies have been working together since January 2005 to discover and develop novel therapies for schizophrenia and other central nervous system (CNS) diseases. The new agreement

Existing investors participating in the financing included Intersouth Partners, Quaker BioVentures, Johnson & Johnson Development, Investor Growth Capital, Polaris Ventures, Mitsui & Company, The Dow Chemical Company, JP

Following the recommendation for regulatory approval under the European decentralized procedure, Toctino (alitretinoin) received national regulatory approval in Germany. Marketing applications for the use of alitretinoin in the

Under the agreement, Biolex will take full responsibility for development and commercialization of Locteron. OctoPlus will retain a royalty interest in the product candidate and provide manufacturing and

The company has announced that Richard Franklin, the company’s chairman, has assumed the newly-created position of executive chairman and Gere diZerega, one of the company’s clinical advisors, has